Alethio raises $90M to target rare blood cancers

Alethio Therapeutics raises $90M Series A for rare blood cancer antibody

Oxford spinout Alethio Therapeutics secured $90 million in Series A funding to advance an antibody treatment for myeloproliferative neoplasms, a group of rare blood cancers.